Highest-materiality recent filing
AdaptHealth reports material cybersecurity incident; patient data exfiltrated via social engineering
Threat actor gained unauthorized access to cloud-based business applications including patient management systems and document storage.
AdaptHealth Q1 net loss widens to $16M, COO replaced; raises revenue guidance
Net revenue $819.8M (+5.4% YoY); net loss $16.0M vs $7.2M loss in Q1 2025.
AdaptHealth closes $1.1B credit facility with reduced pricing and extended maturity to 2031
New facility: $325M term loan, $325M delayed draw term loan, $450M revolver (previously $300M).
Full-year 2025 net loss $70.8M vs net income $90.4M in 2024; includes $128M goodwill impairment.
Net income $24.5M vs $22.9M; YTD free cash flow $140.1M vs $162.7M.
Partnership with a large California-based integrated delivery network; exclusive provider of HME for its 10M+ members.
AdaptHealth Q2 2025 revenue $800.4M, net income $14.7M; lowers FY adjusted EBITDA guidance
Net revenue $800.4M, down 0.7% YoY; net income $14.7M vs $19.4M in prior year.
AdaptHealth closes infusion asset sale, reduces debt by $65M, updates FY2025 guidance
Closed disposition of certain infusion assets in Wellness at Home segment; assets had ~$52M annual revenue and ~$5M annual Adjusted EBITDA.
AdaptHealth Q1 revenue down 1.8% to $778M; net loss widens; guides FY25 lower on asset sales
Net revenue $777.9M (-1.8% YoY); net loss $7.2M vs $2.1M loss prior year.
AdaptHealth reports FY2024 net income of $90.4M vs prior year loss; revenue up 1.9%
FY2024 net revenue $3.261B (+1.9% YoY); net income attributable $90.4M vs net loss $678.9M.
AdaptHealth Q3 net income $22.9M, revenue $805.9M; raises free cash flow guidance
Net income attributable to AdaptHealth of $22.9M vs net loss of $454.1M in Q3 2023.
AdaptHealth corrects private warrant expiry to Nov 8, 2024 from previously reported Nov 20
Notice to private placement warrant holders confirms expiration date is November 8, 2024 at 5:00 PM ET.
New facility: $650M Term Loan A (fully funded) + $300M Revolver, replacing $450M revolver and existing term loan due Jan 2026.
AdaptHealth Q2 revenue $806M (+1.6% YoY); net income $19.4M; narrows guidance
Net revenue $806.0M vs $793.3M YoY; net income $19.4M (+39%); adjusted EBITDA $165.3M (-3.3%).
AdaptHealth President Josh Parnes to resign, Dale Wolf named Board Chair
Josh Parnes steps down as President effective Aug 31, 2024, and from Board Dec 31, 2024.
AdaptHealth Q1 net loss $2.1M, revenue up 6.4% to $792.5M, adj. EBITDA up 18.3%
Net revenue $792.5M (+6.4% YoY); net loss $2.1M vs net income $15.7M prior year.
AdaptHealth appoints Suzanne Foster CEO effective May 20; Richard Barasch to step down
Suzanne Foster, former President of Beckman Coulter Life Sciences (Danaher), named CEO and board member effective May 20, 2024.
FY2023 net revenue $3,200.2M (+7.7% YoY); net loss $678.9M vs $69.3M profit, driven by $830.8M pretax goodwill impairment.
Net revenue $804.0M (+6.3% YoY); net loss $454.1M vs prior year income $16.1M due to $511.9M goodwill impairment.
AdaptHealth and Crispin Teufel mutually terminate CEO employment agreement; interim CEO continues
On September 19, 2023, AdaptHealth and Crispin Teufel mutually terminated his CEO employment agreement.
AdaptHealth extends interim CEO Barasch through Oct 31; new CEO Teufel delayed by court order
Richard Barasch extends interim CEO term to Oct 31, 2023 with $262,500/month base salary and $175K RSU grant.
Linde Group sues to block AdaptHealth's new CEO Crispin Teufel from starting
Linde Inc. and Lincare filed lawsuit Aug 14, 2023 in U.S. District Court for Connecticut.
Net revenue $793.3M, +9.0% YoY; non-acquired net revenue growth 8.7%.
AdaptHealth appoints Crispin Teufel as CEO effective Sept 1, 2023; interim CEO Barasch
Crispin Teufel, former CEO of Lincare Holdings, named CEO of AdaptHealth effective September 1, 2023.
AdaptHealth CEO Stephen Griggs to step down June 30, 2023; search underway
CEO Stephen Griggs resigns by mutual agreement, effective June 30, 2023.
AdaptHealth Q1 revenue +5.4% to $744.6M; adjusted EBITDA -2.7% to $134M
Net revenue $744.6M, up 5.4% YoY; non-acquired growth 4.7%.
AdaptHealth reports Q4 net loss, cuts 2023 guidance on cost pressures and revenue mix
Full-year 2022 net revenue up 21% YoY; net income $69.3M ($0.33/diluted) vs $156.2M ($0.67) in 2021.
AdaptHealth guides FY2023 revenue $3.21-3.29B, adj. EBITDA $690-750M; Q4 prelim near prior ranges
FY2023 net revenue guidance $3.210B-3.290B; Adjusted EBITDA $690M-$750M; capex 9-11% of revenue.
AdaptHealth Q3 revenue $756.5M (+15.8% YoY); net income drops 72% to $16.1M; FY guidance narrowed
Q3 2022 net revenue $756.5M vs $653.3M in Q3 2021, +15.8%.
AdaptHealth Q2 net income drops to $14M; revenue up 18% on CPAP supply challenges
Net revenue $727.6M, up 17.9% YoY; non-acquired revenue declined 0.3%.
the appointment of Daniel McFadden as Chief Operating Officer of the Company, effective as of May 4, 2026
Also on May 4, 2026, the Company appointed Daniel McFadden, the Company’s current Chief Business Systems Officer, as the Company’s Chief Operating Officer.
On May 4, 2026, the Company terminated the employment of Toby Scott Barnhart, the Company’s Chief Operating Officer.
On October 16, 2024, following the recommendation of the nominating and governance committee of AdaptHealth Corp. (the “Company”), the Board of Directors of the Company (the “Board”) appointed Diana L. Nole, age 59, to the Board, effective October 16, 2024.
Toby Scott Barnhart, age 56, has been appointed to serve as the Chief Operating Officer of the Company, effective as of September 23, 2024
On August 13, 2024, AdaptHealth Corp. (the “Company”) informed Shaw Rietkerk of its intention to transition him to a new position as the Company’s Chief Business Officer, by the end of September, 2024, following which Mr. Rietkerk will no longer serve as the Company’s Chief Operating Officer.
the Company and Joshua Parnes, the Company’s President, mutually agreed that Mr. Parnes will resign from all positions that he holds with the Company and its affiliates, effective as of 11:59 p.m. E.D.T. on August 31, 2024
Upon starting as Chief Executive Officer, Ms. Foster will also be appointed to serve as a member of the Company’s board of directors
Suzanne Foster, age 54, has been appointed to serve as the Chief Executive Officer of the Company, effective May 20, 2024.
Mr. Barasch has agreed to continue to serve as the Interim Chief Executive Officer of the Company until October 31, 2023 or such earlier date as determined by the Board of Directors of the Company (the “Transition Date”).
Crispin Teufel, age 47, has been appointed to serve as the Chief Executive Officer of the Company, effective September 1, 2023.
It is further agreed that Mr. Griggs will not stand for reelection as a member of the Company’s Board of Directors (the “Board”) at the Company’s annual meeting currently scheduled for June 21, 2023.
Max materiality 0.80 · Median 0.62 · Most common event leadership